title: Reply to Verlingue, Koscielny and Ferté.
authors.affiliation: European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
authors.forename: S
authors.initials: S
authors.lastname: Litière
authors.affiliation: Department of Medical Oncology, University of Groningen, University Medical Center, Groningen, The Netherlands.
authors.forename: E G E
authors.initials: EG
authors.lastname: De Vries
authors.affiliation: NCIC Clinical trials group, Queens University, Kingston, Canada.
authors.forename: L
authors.initials: L
authors.lastname: Seymour
authors.affiliation: Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, United States.
authors.forename: D
authors.initials: D
authors.lastname: Sargent
authors.affiliation: NCI Cancer Imaging Program, National Institutes of Health, Bethesda, MA, United States.
authors.forename: L
authors.initials: L
authors.lastname: Shankar
authors.affiliation: European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium.
authors.forename: J
authors.initials: J
authors.lastname: Bogaerts
mesh_terms: D001943:Breast Neoplasms / Q000628:therapy*; D015179:Colorectal Neoplasms / Q000628:therapy*; D016208:Databases, Factual; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000628:therapy*; D008297:Male; D015233:Models, Statistical; D047368:Tumor Burden